ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 89 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,600,718 | -12.2% | 333,483 | +37.3% | 0.00% | – |
| Q2 2023 | $1,823,774 | +28.4% | 242,846 | -22.7% | 0.00% | – |
| Q1 2023 | $1,420,123 | -74.1% | 314,186 | -35.4% | 0.00% | -100.0% |
| Q4 2022 | $5,480,803 | +44.4% | 486,318 | +22.6% | 0.00% | 0.0% |
| Q3 2022 | $3,796,000 | +5.7% | 396,637 | -10.7% | 0.00% | – |
| Q2 2022 | $3,592,000 | -44.7% | 443,935 | +15.5% | 0.00% | -100.0% |
| Q1 2022 | $6,497,000 | +18.7% | 384,518 | +51.0% | 0.00% | 0.0% |
| Q4 2021 | $5,473,000 | -9.0% | 254,700 | +212.8% | 0.00% | 0.0% |
| Q3 2021 | $6,014,000 | +8.9% | 81,420 | -19.4% | 0.00% | 0.0% |
| Q2 2021 | $5,523,000 | +1543.8% | 101,009 | +2116.6% | 0.00% | – |
| Q1 2021 | $336,000 | -69.0% | 4,557 | -63.7% | 0.00% | – |
| Q4 2020 | $1,083,000 | +1404.2% | 12,564 | +561.6% | 0.00% | – |
| Q3 2020 | $72,000 | – | 1,899 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $715,272,000 | 67.97% |
| Logos Global Management LP | 3,156,981 | $232,796,000 | 22.72% |
| Vivo Capital, LLC | 4,220,048 | $311,186,000 | 10.94% |
| Foresite Capital Management IV, LLC | 785,945 | $57,956,000 | 6.94% |
| Foresite Capital Management V, LLC | 320,000 | $23,597,000 | 6.94% |
| Board of Trustees of The Leland Stanford Junior University | 518,822 | $38,258,000 | 3.38% |
| Cormorant Asset Management, LP | 881,770 | $65,022,000 | 1.45% |
| Redmile Group, LLC | 978,600 | $72,162,000 | 1.02% |
| SPHERA FUNDS MANAGEMENT LTD. | 130,351 | $9,612,000 | 0.74% |
| Artal Group S.A. | 525,000 | $38,714,000 | 0.68% |